Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial

Annals of Neurology

Volumn 27, Issue 6, 1990, Pages 591-605

  Wolinsky, ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE; DRUG EFFICACY; DRUG TOXICITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CYCLOSPORINS; DOUBLE-BLIND METHOD; FEMALE; HUMAN; KIDNEY DISEASES; MALE; MIDDLE AGE; MULTICENTER STUDIES; MULTIPLE SCLEROSIS; SUPPORT, NON-U.S. GOV'T;

EID: 0025345601     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410270603     Document Type: Article

References (55)

1. The incidence and prevalence of reported multiple sclerosis
2. Autoimmunity in demyelinating diseases
3. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia‐positive macrophages in lesions of different ages
4. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions
5. T cell subsets in multiple sclerosis. Gradients at plaque borders and differences in nonplaque regions
6. Interferon‐gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions
7. The basis of intra‐blood‐brain‐barrier IgG synthesis
8. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis
9. HLA‐DP antigens are involved in the susceptibility to multiple sclerosis
10. Selective loss of a subset of T helper cells in active multiple sclerosis
11. Selective loss of the suppressor‐inducer T‐cell subset in progressive multiple sclerosis. Analysis with anti‐2H4 monoclonal antibody
12. Serial immune evaluation of cyclosporine‐ and placebo‐treated multiple sclerosis patients
13. Activated suppressor cell dysfunction in progressive multiple sclerosis
14. T cells in multiple sclerosis and inflammatory central nervous system diseases
15. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs placebo–final report
16. Intensive immunosuppression in progressive multiple sclerosis
17. A double‐blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis
18. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system
19. Cyclosporine and the immune response: basic aspects
20. T‐lymphocyte inhibition by cyclosporine. Potential mechanisms
21. Cyclosporine: mechanism of action
22. Mechanisms of action of cyclosporine: effect on cells of the immune system and on sub‐cellular events in T cell activation
23. Cyclosporine: a new immunosuppressive agent for agent for organ transplantation
24. Treatment of intraocular inflammatory disease with cyclosporin A
25. Effects of cyclosporine immunosuppression in insulin‐dependent diabetes mellitus of recent origin
26. Immunosuppression by cyclosporine A of allergic encephalomyelitis
27. The influence of cyclosporine A on the development of actively induced and passively transferred experimental allergic encephalomyelitis
28. Use of cyclosporine in neurological autoimmune disease
29. Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis: results of the German multicenter study
30. Randomized double blind controlled trial of cyclosporin in multiple sclerosis
31. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)
32. Double‐blind trial of linoleate supplementation of the diet in multiple sclerosis
33. Polyunsaturated fatty acids in the treatment of acute remitting multiple sclerosis
34. Some thoughts on clinical trials, especially problems of multiplicity
35. Field testing of a minimal record of disability in multiple sclerosis; the United States and Canada
36. Criteria and uses of the Minimal Record of Disability in multiple sclerosis
37. Quantifying the neurologic examination
38. Cooperative study in the evaluation of therapy in multiple sclerosis; ACTH vs placebo in acute exacerbations. Preliminary report
39. Multiple Sclerosis Study Group. Measuring disease status in a clinical trial of cyclosporine in chronic progressive multiple sclerosis. Should a unified rating scale be used?
40. Analysis of covariance using the rank transformation
41. Loss of patients in clinical trials that measure long‐term survival following myocardial infarction
42. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis
43. Association between cyclosporin neurotoxicity and hypomagnesaemia
44. The natural history of multiple sclerosis
45. Side effects of systemic cyclosporine in patients not undergoing transplantation
46. Renal function in patients with autoimmune diseases treated with cyclosporine
47. Cancers after cyclosporine therapy
48. Systemic hypertension associated with cyclosporine: a review
49. Planning the duration of a comparative clinical trial with loss to follow‐up and a period of continued observation
50. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis
51. Optimizing cyclosporine therapy: dose, levels, and monitoring